ITGAX and non-small cell lung carcinoma: Additionally, we noticed both ITGAL and ITGAX effectively predict NSCLC response to PD1-based ICB treatment as individual genes, with a robustness matching or outperforming other established ICB biomarker-derived predictions (Figure 3C).